Displaying 1 - 12 of 149
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: Quantitative hepatitis B surface antigen today and tomorrow (Complete Session) - EASL Congress 2024

View
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: A roadmap to functional cure (Complete Session) - EASL Congress 2024

View
Viral Hepatitis
6

AbbVie: "Test + treat = Cure. Is the HCV elimination formula really that simple?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
7

GSK: "Practical tips towards providing holistic care to patients with PBC" - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Viral Hepatitis
5

Gilead: "Headlines In Hepatitis Delta: The Latest Advances In Care in Hepatitis Delta" - EASL Congress 2023

View
Viral Hepatitis
3

Gilead: “From Headlines To The Clinic: Expert Approaches To Patient Care in Hepatitis Delta” - EASL Congress 2023

View
Viral Hepatitis
1

GSK: "Looking To The Future Of Hepatitis B: An Expert Review Of Quantitative Hepatitis B Surface Antigen Assessment” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Ipsen: "Scratching beyond the surface in PBC: From current unmet medical needs to future prospects" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Mirum Pharmaceuticals, Inc: "Meet the Experts in Cholestatic Liver Disease" - EASL Congress 2023

View
Displaying 1 - 12 of 149